A postdoctoral training position is available in the laboratory of Dr. Jacques Lux, in the in the Translational Research for Ultrasound Theranostics (TRUST) program within the Department of Radiology at UT Southwestern Medical Center to study, develop and translate enzyme-based nanoparticles for in vivo detection of disease and therapy. Apply here.

Jacques Lux, Ph.D., earned his doctorate in chemistry at the University of Strasbourg under the guidance of Nobel laureate Jean-Pierre Sauvage. His Ph.D. projects aimed at designing and developing synthetic molecular machines reminiscent of biological systems.

Following his Ph.D., Dr. Lux conducted postdoctoral research at the faculty of pharmacy in Strasbourg, where he developed activatable optical probes for the detection of viral RNA. He then came to the United States to train in supramolecular chemistry in Professor Julius Rebek Jr.’s laboratory at the Scripps Research Institute in La Jolla, California. Dr. Lux received another postdoctoral research opportunity at the University of California – San Diego (UCSD), applying his skills in organic and coordination chemistry to the field of material science, and then became a Research Scientist to develop and translate theranostics for imaging and drug delivery.

While at UCSD, he designed and synthetized a novel MR contrast agent that incorporated gadolinium that was chelated and linked to hydrogel nanoparticles (nanogels). The advantage of this strategy is not only the development of high relaxivity T1 agents, but also minimizing demetallation. The versatility of this platform was demonstrated by incorporating 64Cu instead of gadolinium that allowed for in vivo PET/CT imaging of cancer. Dr. Lux also participated in the development of novel activatable optical nanoprobes for the detection of inflammation.

In 2015, Dr. Lux joined the newly established Translational Research in Ultrasound Theranostics (TRUST) Program at UT Southwestern in the Department of Radiology, which focuses on the development of targeted and activatable ultrasound agents that not only aid in cancer detection, but also under ultrasound control, release drugs and/or destroy tumors with high-intensity focused ultrasound. Dr. Lux became assistant director of the TRUST program in 2017.

In November 2017, Dr. Lux received the 2017 Docstars Award by The Cary Council in recognition and support of promising early-stage research.